Aptimmune Biologics specializes in the development and application of prophylactic measures against viral diseases of swine. Our current focus is bringing into the market effective prophylaxis against Porcine Reproductive and Respiratory Syndrome (PRRS) virus. Aptimmune utilizes novel technologies to create effective vaccines against PRRSV such as the proprietary pig alveolar macrophage cell line ZMAC.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/13/15 | $2,750,000 | Series A |
Arsenal Capital Partners Fox Ventures | undisclosed |
